{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001426","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.479847+00:00","generated_at":"2026-06-18T12:32:27.658136+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anika Q4 revenue up 11% to $39.6M; net loss $4.9M; FY2023 guidance $158-163M","bullets":["Q4 revenue $39.6M (+11% YoY); OA Pain Mgmt $23.7M (+20%), Joint Preservation $14.3M (+8%).","Q4 net loss ($4.9M) or ($0.34) per share; adjusted net loss ($3.0M) or ($0.21) per share.","Full year 2022 revenue $156.2M (+6%); net loss ($14.9M) vs net income $4.1M in 2021.","FY2023 revenue guidance $158-163M (1-4% growth); OA Pain Mgmt $93.5-96M, Joint Preservation $55.5-58M.","Hyalofast Phase III trial 199/200 enrolled; Cingal engaging FDA; RevoMotion limited release initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001426","json":"https://secwatch.observer/filing/0001171843-23-001426.json","markdown":"https://secwatch.observer/filing/0001171843-23-001426.md","text":"https://secwatch.observer/filing/0001171843-23-001426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/0001171843-23-001426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/f8k_030623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T12:32:27.658136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52039dc64232740ae0043f8e026f14be682d4517","claim":"Anika Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $39.6 million, net income ($4.9) million, EPS ($0.34) per share.","evidence_excerpt":"Revenue in the fourth quarter of 2022 was $39.6 million, up 11% compared with $35.8 million in the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/0001171843-23-001426-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$39.6 million"},{"label":"Net income","value":"($4.9) million"},{"label":"EPS","value":"($0.34) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"aed583c8863279e2eedd2c143c62846773d1942a","claim":"Anika Therapeutics, Inc. reported fiscal year ended December 31, 2022 results: net income ($14.9) million, EPS ($1.02) per share.","evidence_excerpt":"Revenue for fiscal 2022 increased 6% to $156.2 million, compared with $147.8 million in 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/0001171843-23-001426-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2022"},{"label":"Net income","value":"($14.9) million"},{"label":"EPS","value":"($1.02) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"aed583c8863279e2eedd2c143c62846773d1942a","claim":"Anika Therapeutics, Inc. reported fiscal year ended December 31, 2022 results: net income ($14.9) million, EPS ($1.02) per share.","evidence_excerpt":"Net loss was ($14.9) million, or ($1.02) per share, compared to net income of $4.1 million, or $0.28 per diluted share, in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/0001171843-23-001426-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2022"},{"label":"Net income","value":"($14.9) million"},{"label":"EPS","value":"($1.02) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c11ff6c12ab6a43b4a6e552153c2b57b5e1472d2","claim":"Anika Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: net income ($4.9) million, EPS ($0.34) per share.","evidence_excerpt":"Net loss was ($4.9) million, or ($0.34) per share, compared to net loss of ($5.8) million, or ($0.40) per share, in the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/0001171843-23-001426-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Net income","value":"($4.9) million"},{"label":"EPS","value":"($0.34) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}